Sex-associated molecular differences for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Genomics

Background:

• Immune checkpoint blockade (ICB) therapies have improved cancer patient survival.
• Existing meta-analyses provide conflicting conclusions regarding sex differences in immunotherapy response.
• Understanding these sex-based differences is crucial for personalized cancer treatment.

Purpose of the Study:

• To investigate potential differences in cancer immunotherapy efficacy between male and female patients.
• To identify molecular factors associated with immunotherapy response across different cancer types.
• To analyze sex-based immune profiles in cancer patients treated with ICB.

Main Methods:

• Summarized existing meta-analyses on gender and immunotherapy response.
• Analyzed molecular profiling data from ICB-treated patients.
• Conducted comprehensive analyses using The Cancer Genome Atlas (TCGA) and validated findings in independent datasets.

Main Results:

• Meta-analyses show inconsistent conclusions on sex-associated immunotherapy response.
• Molecular profiling reveals divergent patterns of sex bias in immune features across multiple cancer types.
• Findings were validated in independent patient cohorts.

Conclusions:

• Pooling data across diverse cancer types in meta-analyses limits definitive conclusions on sex-based immunotherapy efficacy.
• Significant sex-associated molecular differences exist in immune features across various cancers.
• Future research should incorporate omics profiling to elucidate sex-specific mechanisms in immunotherapy response.